



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 5/06; A61K 38/05	A1	(11) International Publication Number: WO 98/46626 (43) International Publication Date: 22 October 1998 (22.10.98)
(21) International Application Number: PCT/US98/07159		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 13 April 1998 (13.04.98)		
(30) Priority Data: 60/069,322 14 April 1997 (14.04.97) US		
(71) Applicant: COR THERAPEUTICS, INC. [US/US]; 256 E. Grand Avenue, South San Francisco, CA 94080 (US).		
(72) Inventors: ZHU, Bing-Yan; Apartment K302, 1125 Balclutha Drive, Foster City, CA 94404 (US). SCARBOROUGH, Robert, M.; 2544 Belmont Canyon Road, Belmont, CA 94002 (US). SU, Ting; 3222 Upper Lock Avenue, Belmont, CA 94002 (US).		
(74) Agents: ADLER, Reid, G. et al.; Morgan, Lewis & Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).		

(54) Title: SELECTIVE FACTOR Xa INHIBITORS

(57) Abstract

Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful *in vitro* or *in vivo* for preventing or treating coagulation disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CP	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

Selective Factor Xa InhibitorsField of the Invention

This invention relates to a novel class of cyclic diaza compounds which are potent and highly selective inhibitors of factor Xa or factor Xa when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g. thrombin, fVIIa, fIXa) or the fibrinolytic cascades (e.g. plasminogen activators, plasmin).

Background of the Invention

Blood coagulation protects mammalian species when the integrity of the blood vessel wall is damaged and uncontrolled loss of blood threatens survival. Coagulation, resulting in the clotting of blood, is an important component of hemostasis. Under normal hemostatic circumstances, there is maintained an acute balance of clot formation and clot removal (fibrinolysis). The blood coagulation cascade involves the conversion of a variety of inactive enzymes (zymogens) into active enzymes, which ultimately convert the soluble plasma protein fibrinogen into an insoluble matrix of highly cross-linked fibrin. (See Davie, *et al.*, "The Coagulation Cascade: Initiation, Maintenance and Regulation" Biochemistry 30:10363-10370 (1991)). Blood platelets which adhere to damaged blood vessels are activated and incorporated into the clot and thus play a major role in the initial formation and stabilization of hemostatic "plugs". In certain diseases of the cardiovascular system, deviations from normal hemostasis push the balance of clot formation and clot dissolution towards life-threatening thrombus formation when thrombi occlude blood flow in coronary vessels (myocardial infarctions) or limb and pulmonary veins (venous thrombosis). Although platelets and blood coagulation are both involved in thrombus formation, certain components of the coagulation cascade are primarily responsible for the amplification or acceleration of the processes involved in platelet aggregation and fibrin deposition.

A key enzyme in the coagulation cascade, as well as in hemostasis, is thrombin. Thrombin is intimately involved in the process of thrombus formation, but under normal

circumstances can also play an anticoagulant role in hemostasis through its ability to convert protein C into activated protein C in a thrombomodulin-dependent manner.

Thrombin plays a central role in thrombosis through its ability to catalyze the penultimate conversion of fibrinogen into fibrin and through its potent platelet activation activity. Direct or indirect inhibition of thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol. 5:411-436 (1994). The major classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e. heparins, low-molecular weight heparins and coumarins). Thrombin is generated at the convergence of the intrinsic and extrinsic coagulation pathways by the prothrombinase complex. The prothrombinase complex is formed when activated Factor X (factor Xa) and its non-enzymatic cofactor, factor Va assemble on phospholipid surfaces in a Ca^{+2} -dependent fashion as reviewed by Mann, *et al.*, "Surface-Dependent Reactions of the Vitamin K-Dependent Enzymes", Blood 76:1-16 (1990). The prothrombinase complex converts the zymogen prothrombin into the active procoagulant thrombin.

The location of the prothrombinase complex at the convergence of the intrinsic and extrinsic coagulation pathways, and the significant amplification of thrombin generation (393,000-fold over uncomplexed factor Xa) mediated by the complex at a limited number of targeted catalytic units present at vascular lesion sites, suggests that inhibition of thrombin generation is an ideal method to block uncontrolled procoagulant activity. Unlike thrombin, which acts on a variety of protein substrates as well as at a specific receptor, factor Xa appears to have a single physiologic substrate, namely prothrombin.

Plasma contains an endogenous inhibitor of both the factor VIIa-tissue factor (TF) complex and factor Xa called tissue factor pathway inhibitor (TFPI). TFPI is a Kunitz-type protease inhibitor with three tandem Kunitz domains. TFPI inhibits the TF/fVIIa complex in a two-step mechanism which includes the initial interaction of the second Kunitz domain of TFPI with the active site of factor Xa, thereby inhibiting the

proteolytic activity of factor Xa. The second step involves the inhibition of the TF/fVIIa complex by formation of a quaternary complex TF/fVIIa/TFPI/fXa as described by Girard, *et al.*, "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-associated Coagulation Inhibitor". Nature 338:518-520 (1989).

5 Polypeptides derived from hematophagous organisms have been reported which are highly potent and specific inhibitors of factor Xa. U.S. Pat. No. 4,588,587 awarded to Gasic, describes anticoagulant activity in the saliva of the Mexican leech, *Haementeria officinalis*. A principal component of this saliva is shown to be the polypeptide factor Xa inhibitor, antistasin, by Nutt, *et al.*, "The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", J. Biol. Chem. 263:10162-10167 (1988).

10 Another potent and highly specific inhibitor of Factor Xa, tick anticoagulant peptide, has been isolated from the whole body extract of the soft tick *Ornithodoros moubata*, as reported by Waxman, *et al.*, "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa". Science 248:593-596 (1990).

15 Other polypeptide type inhibitors of factor Xa have been reported including the following citations by: Condra, *et al.*, "Isolation and Structural Characterization of a Potent Inhibitor of Coagulation Factor Xa from the Leech *Haementeria ghilianii*". Thromb. Haemost. 61:437-441 (1989); Blankenship, *et al.*, "Amino Acid Sequence of Ghilanten: Anti-coagulant-antimetastatic Principle of the South American Leech, *Haementeria ghilianii*", Biochem. Biophys. Res. Commun. 166:1384-1389 (1990); Brankamp, *et al.*, "Ghilantens: Anticoagulants. Antimetastatic Proteins from the South American Leech *Haementeria ghilianii*", J. Lab. Clin. Med. 115:89-97 (1990); Jacobs, *et al.*, "Isolation and Characterization of a Coagulation Factor Xa Inhibitor from Black Fly Salivary Glands", Thromb. Haemost. 64:235-238 (1990); Rigbi, *et al.*, "Bovine Factor Xa Inhibiting Factor and Pharmaceutical Compositions Containing the Same", European Patent Application, 352,903 (1990); Cox, "Coagulation Factor X Inhibitor From the Hundred-pase Snake *Deinagkistrodon acutus* venom", Toxicon 31:1445-1457 (1993);

Cappello, *et al.*, "Ancylostoma Factor Xa Inhibitor: Partial Purification and its Identification as a Major Hookworm-derived Anticoagulant *In Vitro*", *J. Infect. Dis.* 167:1474-1477 (1993); Seymour, *et al.*, "Ecotin is a Potent Anticoagulant and Reversible Tight-binding Inhibitor of Factor Xa", *Biochemistry* 33:3949-3958 (1994).

5 Factor Xa inhibitory compounds which are not large polypeptide-type inhibitors have also been reported including: Tidwell, *et al.*, "Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", *Thromb. Res.* 19:339-349 (1980); Turner, *et al.*, "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", *Biochemistry* 25:4929-4935 (1986); Hitomi, *et al.*,
10 "Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System", *Haemostasis* 15:164-168 (1985); Sturzebecher, *et al.*, "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", *Thromb. Res.* 54:245-252 (1989); Kam, *et al.*, "Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", *Biochemistry* 27:2547-2557 (1988); Hauptmann, *et al.*, "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors", *Thromb. Haemost.* 63:220-223 (1990); Miyadera, *et al.*, Japanese Patent Application JP 6327488 (1994); Nagahara, *et al.*, "Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", *J. Med. Chem.* 37:1200-1207 (1994); Vlasuk, *et al.*, "Inhibitors of Thrombosis", WO 93/15756; and Brunck, *et al.*, "Novel Inhibitors of Factor Xa", WO 94/13693. Al-obeidi, *et al.*, "Factor Xa Inhibitors", WO 95/29189, discloses pentapeptide X1-Y-I-R-X2 derivatives as factor Xa inhibitors. Said compounds are useful for inhibiting blood clotting in the treatment of thrombosis, stroke, and myocardial infarction.

25

Summary Of The Invention


The present invention relates to novel peptide mimetic analogs, their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives.

In another aspect, the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the compounds of this invention and a pharmaceutically acceptable carrier. These compositions are useful as potent and specific inhibitors of blood coagulation in mammals.

5 In yet another aspect, the invention relates to methods of using these inhibitors as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis
10 in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.

In other aspects of the invention compounds are provided which are useful as diagnostic reagents.

15 In preferred embodiments, the present invention provides compounds of general formula I:



Wherein:

R¹ is selected from the group consisting of H, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₃alkylaryl, C₁₋₃alkyl-C₃₋₈cycloalkyl and aryl and R² is H, or R¹ and R² are taken together to form a carbocyclic ring;

m is an integer from 0-2;

n is an integer from 0-6;

k is an integer from 0-1;

p is an integer from 0-1;


q is an integer from 0-3;

r is an integer from 0-4;

s is an integer from 0-1;

5 t is an integer from 0-4;

A is selected from the group consisting of R³, -NR³R⁴,



where R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of H, -OH, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl; R⁷ is selected from the group consisting of H, C₁₋₆alkyl, 10 aryl and C₁₋₄alkylaryl, or can be taken together with R⁵ or R⁶ to form a 5-6 membered ring; and R⁸ is selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl, or can be taken together with R⁶ to form a 5-6 membered ring;

Q is selected from the group consisting of a direct link, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₆alkenyl, C₁₋₆alkenylaryl, aryl, and a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;

D is selected from the group consisting of a direct link, -CO-, -SO₂-, -O-CO-, -NR⁹-SO₂- and -NR⁹-CO-, where R⁹ is selected from the group consisting of H, -OH, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl;

X is O or H₂;


20 Y is O or H₂;

K is selected from the group consisting of R²⁸O- and R²⁹R³⁰N-, where R²⁸, R²⁹ and R³⁰ are independently selected from the group consisting of H, C₁₋₆alkyl, C₀₋₃alkylaryl, C₀₋₃alkylC₃₋₈cycloalkyl, C₀₋₃alkylheterocycle; and where R²⁹ and R³⁰ can be taken together to form a five to ten membered heterocyclic ring system containing 1-4

heteroatoms selected from the group consisting of N, O and S;

E is selected from the group consisting of a direct link, C₃₋₈cycloalkyl, aryl, and a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;

5 G is selected from the group consisting of R¹⁰, -NR¹⁰R¹¹,




where R¹⁰, R¹¹, R¹² and R¹³ are independently selected from the group consisting of H,

-OH, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl; R¹⁴ is selected from the group consisting of H,


C₁₋₆alkyl, aryl and C₁₋₄alkylaryl, or can be taken together with R¹² or R¹³ to form a 5-6

10 membered ring; and R¹⁵ is selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl, or can be taken together with R¹³ to form a 5-6 membered ring; with the proviso that when G is R¹⁰, then E must contain at least one N atom;

W is selected from the group consisting of H,



15 where R¹⁶ and R¹⁷ are independently selected from the group consisting of H, C₁₋₃alkyl and aryl; and Z is selected from the group consisting of H, -COOR¹⁸, -CONR¹⁸R¹⁹, -CF₃, -CF₂CF₃ and a group having the formula:



where:

R¹⁸ and R¹⁹ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl;


U is selected from the group consisting of -O-, -S-, -N- and -NH-; and

V is selected from the group consisting of -O-, -S-, -N- and -NH-; with the proviso
5 that at least one of U or V is -N- or -NH-;

R²⁰ is selected from the group consisting of H, C₁₋₆alkyl, C₂₋₆alkenyl, C₀₋₆alkylaryl, C₂₋₆alkenylaryl, C₀₋₆alkylheterocyclo, C₂₋₆alkenylheterocyclo, -CF₃ and -CF₂CF₃.

J is selected from the group consisting of -S-, -SO-, -SO₂-, -O- and -NR²¹-, where R²¹ is selected from the group consisting of H, C₁₋₆alkyl and benzyl; and

10 L is selected from the group consisting of:



a C₆₋₁₀ heterocyclic ring system substituted by R²⁴ and R²⁵ and containing 1-4 heteroatoms selected from N, S and O;

where d is an integer from 0-2;

15 R²² and R²³ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl, C₁₋₆alkylaryl, -COOR²⁶, -CONR²⁶R²⁷, -CN and -CF₃;

R²⁴ and R²⁵ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl, C₁₋₆alkylaryl, C₁₋₄alkyloxy, halogen, -NO₂, -NR²⁶R²⁷, -NR²⁶COR²⁷, -OR²⁶, -OCOR²⁶, -COOR²⁶, -CONR²⁶R²⁷, -CN, -CF₃, -SO₂NR²⁶R²⁷ and C₁₋₆alkyl-OR²⁶; and

20 R²⁶ and R²⁷ are independently selected from the group consisting of H, C₁₋₆alkyl, C₁₋₃alkylaryl and aryl; and all pharmaceutically acceptable salts and optical isomers thereof.

Detailed Description Of The InventionDefinitions

In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.

- 5 The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms. The term "cycloalkyl" refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 12 carbon atoms, preferably 3 to 7 carbon atoms.
- 10 The term "alkenyl" refers to unsaturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having at least one double bond and having the number of carbon atoms specified.
- 15 The term "aryl" refers to an unsubstituted or substituted aromatic ring(s), substituted with one, two or three substituents such as, by way of example and not limitation,
- C₁₋₆ alkoxy, C₁₋₆ alkyl, C₁₋₆ alkylamino, hydroxy, halogen, cyano (-CN), mercapto, nitro (-NO₂), thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy, carboxamide, -NR'R'', -NR'COR'', -OR, -OCOR, -COOR, -CONR'R'', -CF₃, -SO₂NR'R'' and C₁₋₆alkyl-OR, aryl, C₁₋₆alkylaryl (where the R groups can be H, C₁₋₆alkyl, C₁₋₃alkylaryl and aryl), including but not limited to carbocyclic aryl, heterocyclic aryl, biaryl and triaryl groups and the like, all of which may be optionally substituted. Preferred aryl groups include phenyl, halophenyl, C₁₋₆ alkylphenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and aromatic heterocyclics or heteroaryls, the latter of which is an aryl group containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Aryl groups preferably have 5-14 carbon atoms making up the ring(s) structure, while heteroaryls preferably have 1-4 heteroatoms, with the remaining 4-10 atoms being carbon atoms.
- 20 The terms "heterocyclo" and "hetero cyclic ring system" as used herein refers to any saturated or unsaturated mono- or bicyclic ring system, containing from one to four
- 25

heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur. Typical examples of monocyclic ring systems include piperidinyl, pyrrolidinyl, pyridinyl, piperidonyl, pyrrolidonyl and thiazolyl, while examples of bicyclic ring systems include benzimidazolyl, benzothiazolyl and benzoxazolyl, all of which may be substituted.

5 The term "carbocyclic ring" as used herein refers to any saturated or unsaturated ring containing from three to six carbon atoms.

The terms "alkylaryl" and "alkenylaryl" as used herein refer to an alkyl group or alkenyl group, respectively, having the number of carbon atoms designated, appended to one, two, or three aryl groups. The term benzyl as used herein refers to -CH₂-C₆H₅.

10 The term "alkyloxy" as used herein refers to an alkyl group linked to an oxygen atom, such as methoxy, ethoxy, and so forth.

The term "halogen" as used herein refer to Cl, Br, F or I substituents.

The term "direct link" as used herein refers to a bond directly linking the substituents on each side of the direct link. When two adjacent substituents are defined as each being a "direct link", it is considered to be a single bond.

15 Two substituents are "taken together to form a 5-6 membered ring" means that an ethylene or a propylene bridge, respectively, is formed between the two substituents.

The term "pharmaceutically acceptable salts" includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.

20 "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic

acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum bases, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.

"Biological property" for the purposes herein means an *in vivo* effector or antigenic function or activity that is directly or indirectly performed by a compound of this invention. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it. The biological properties of the compounds of the present invention can be readily characterized by the methods described in Examples 17 and 18 and by such other methods as are well known in the art.

In addition, the following abbreviations are used in this application:

"Bn" refers to benzyl.

"Boc" refers to t-butoxycarbonyl.

"BOP" refers to benzotriazol-1-yloxy-tris-(dimethylamino) phosphonium hexafluorophosphate.

"Bu" refers to butyl.

5

"CBZ" refers to carbobenzoxy.

"DIEA" refers to diisopropylethylamine.

"DMF" refers to N,N-dimethylformamide.

"EDC" refers to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

10

"Et" refers to ethyl.

"Et₂O" refers to diethyl ether.

"EtOAc" refers to ethyl acetate.

"HF" refers to hydrogen fluoride.

"HOAc" refers to acetic acid.

15

"LiN(TMS)₂" refers to lithium bis-trimethyl silyl amide.

"Me" refers to methyl.

"Ph" refers to phenyl.

"pTsOH" refers to *p*-toluene sulfonic acid.

"TFA" refers to trifluoroacetic acid.

20

"THF" refers to tetrahydrofuran.

"Tos" refers to *p*-toluenesulfonyl.

25

In the compounds of this invention, carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof. The syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods

known in the art. Each of the asymmetric carbon atoms, when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention. In the processes described above, the final products may, in some cases, contain a small amount of diastereomeric or enantiomeric products; however, these products do not affect their therapeutic or diagnostic application.


In all of the peptides of the invention, one or more amide linkages (-CO-NH-) may optionally be replaced with another linkage which is an isostere such as -CH₂NH-, -CH₂S-, -CH₂-O-, -CH₂CH₂-, -CH=CH- (cis and trans), -COCH₂-, -CH(OH)CH₂-, -CH₂SO-, and -CH₂SO₂-.

The following references describe preparation of peptide analogs which include these alternative-linking moieties: Spatola, "Peptide Backbone Modifications" (general review) Vega Data, Vol. 1, Issue 3, (March 1983); Spatola, "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins," (general review) B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Morley, Trends Pharm. Sci. (general review) pp. 463-

468 (1980); Hudson, *et al.*, Int. J. Pept. Prot. Res. 14:177-185 (1979) (-CH₂NH-, -CH₂CH₂-); Spatola, *et al.*, Life Sci. 38:1243-1249 (1986) (-CH₂-S); Hann, J. Chem. Soc. Perkin Trans. I pp.307-314 (1982) (-CH=CH-, cis and trans); Almquist, *et al.*, J. Med. Chem. 23:1392-1398 (1980) (-COCH₂-); Jennings-White, *et al.*, Tetrahedron Lett. 23:2533 (-COCH₂-) (1982); Szelke, *et al.*, European Application EP 45665; CA:97:39405 (1982) (-CH(OH)CH₂-); Holladay, *et al.*, Tetrahedron Lett. 24:4401-4404 (1983) (-CH(OH)CH₂-); and Hruby, Life Sci. 31:189-199 (1982) (-CH₂-S-).

Preferred Embodiments

This invention relates to a new class of cyclic diaza compounds selected from those of general formula I which are potent and specific inhibitors of Xa, their pharmaceutically acceptable compositions thereof, and the methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis:



Wherein:

R¹ is selected from the group consisting of H, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₄alkylaryl,
C₁₋₄alkyl-C₃₋₈cycloalkyl and aryl and R² is H, or R¹ and R² are taken together to form a
carbocyclic ring;

m is an integer from 0-2;

n is an integer from 0-6;

k is an integer from 0-1;

p is an integer from 0-1;


q is an integer from 0-3;

r is an integer from 0-4;

s is an integer from 0-1;

t is an integer from 0-4;

A is selected from the group consisting of R³, -NR³R⁴,



where R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of H, -OH, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl; R⁷ is selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl, or can be taken together with R⁵ or R⁶ to form a 5-6 membered ring; and R⁸ is selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl.

or can be taken together with R⁶ to form a 5-6 membered ring;

Q is selected from the group consisting of a direct link, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₆alkenyl, C₁₋₆alkenylaryl, aryl, and a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;

5 D is selected from the group consisting of a direct link, -CO-, -SO₂-, -O-CO-, -NR⁹-SO₂- and -NR⁹-CO-, where R⁹ is selected from the group consisting of H, -OH, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl;


X is O or H₂;

Y is O or H₂;

10 K is selected from the group consisting of R²⁸O- and R²⁹R³⁰N-, where R²⁸, R²⁹ and R³⁰ are independently selected from the group consisting of H, C₁₋₆alkyl, C₀₋₃alkylaryl, C₀₋₃alkylC₃₋₈cycloalkyl, C₀₋₃alkylheterocycle; and where R²⁹ and R³⁰ can be taken together to form a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;

15 E is selected from the group consisting of a direct link, C₃₋₈cycloalkyl, aryl, and a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;


G is selected from the group consisting of R¹⁰, -NR¹⁰R¹¹,




20 where R¹⁰, R¹¹, R¹² and R¹³ are independently selected from the group consisting of H, -OH, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl; R¹⁴ is selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl, or can be taken together with R¹² or R¹³ to form a 5-6 membered ring; and R¹⁵ is selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl, or can be taken together with R¹³ to form a 5-6 membered ring; with the

proviso that when G is R¹⁰, then E must contain at least one N atom:

W is selected from the group consisting of H,



where R¹⁶ and R¹⁷ are independently selected from the group consisting of H, C₁₋₃alkyl and aryl; and Z is selected from the group consisting of H, -COOR¹⁸, -CONR¹⁸R¹⁹, -CF₃, -CF₂CF₃, and a group having the formula:



where:

R¹⁸ and R¹⁹ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl;


U is selected from the group consisting of -O-, -S-, -N- and -NH-; and

V is selected from the group consisting of -O-, -S-, -N- and -NH-; with the proviso that at least one of U or V is -N- or -NH-;

R²⁰ is selected from the group consisting of H, C₁₋₆alkyl, C₂₋₆alkenyl, C₀₋₆alkylaryl, C₂₋₆alkenylaryl, C₀₋₆alkylheterocyclo, C₂₋₆alkenylheterocyclo, -CF₃ and -CF₂CF₃.

J is selected from the group consisting of -S-, -SO-, -SO₂-, -O- and -NR²¹-, where R²¹ is selected from the group consisting of H, C₁₋₆alkyl and benzyl; and

L is selected from the group consisting of:



a C₆₋₁₀ heterocyclic ring system substituted by R²⁴ and R²⁵ and containing 1-4 heteroatoms selected from N, S and O;


where α is an integer from 0-2;

R²² and R²³ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl, C₁₋₆alkylaryl, -COOR²⁶, -CONR²⁶R²⁷, -CN and -CF₃;

5 R²⁴ and R²⁵ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl, C₁₋₆alkylaryl, C₁₋₄alkyloxy, halogen, -NO₂, -NR²⁶R²⁷, -NR²⁶COR²⁷, -OR²⁶, -OCOR²⁶, -COOR²⁶, -CONR²⁶R²⁷, -CN, -CF₃, -SO₂NR²⁶R²⁷ and C₁₋₆alkyl-OR²⁶; and

10 R²⁶ and R²⁷ are independently selected from the group consisting of H, C₁₋₆alkyl, C₁₋₃alkylaryl and aryl; and all pharmaceutically acceptable salts and optical isomers thereof.

A preferred embodiment of compounds of general structural formula I have the following stereochemistry:



Preferred R¹ substituents are H and C₁₋₆alkyl; more preferably H and methyl; most preferably H. R² is preferably H.

15 The integer "m" is preferably from 0-1; more preferably 0.

The integer "n" is preferably from 0-4.

The integer "r" is preferably 3.

The integer "s" is preferably 0.

The integer "t" is preferably from 1-2.

20 The integer "k" is preferably 0.

The integer "p" is preferably 0.

The integer "q" is preferably from 1-2.

In the various "A" substituents, it is preferred that R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of H or C₁₋₆alkyl; and are more

preferably independently selected from the group consisting of H or methyl. It is also preferred that R⁷ is H, C₁₋₆alkyl or taken together with R⁵ or R⁶ to form a 5-6 membered ring; and is more preferably H or methyl. It is also preferred that R⁸ is H, C₁₋₆alkyl or taken together with R⁶ to form a 5-6 membered ring; and is more preferably H or methyl.


5 Preferred "Q" substituents are a direct link, C₁₋₄alkyl, C₃₋₈cycloalkyl, aryl, or a five to ten membered heterocyclic ring system. More preferably, Q is C₁₋₄alkyl, aryl, or a five to ten membered heterocyclic ring system.

D is preferably a direct link, -CO- or -SO₂-.

X is preferably H₂.

10 Y is preferably O.

K is preferably selected from the group consisting of R²⁸O- and R²⁹R³⁰N-, where R²⁸, R²⁹ and R³⁰ are independently selected from the group consisting of H, C₁₋₆alkyl, C₀₋₃alkylaryl, C₀₋₃alkylC₃₋₈cycloalkyl, C₀₋₃alkylheterocycle; and where R²⁹ and R³⁰ can be taken together to form a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S. More preferably, K is selected from the group consisting of HO-, CH₃O-, CH₃CH₂O-, H₂N-, (CH₃)₂N-,




and

15 E is preferably a direct link.


In the "G" substituent, it is preferred that R¹⁰, R¹¹, R¹² and R¹³ are independently selected from the group consisting of H and C₁₋₆alkyl, more preferably H and methyl.

20 W is preferably:




where R¹⁶ is preferably H and R¹⁷ is preferably H.

Z is preferably H, -COOR¹⁸, -CONR¹⁸R¹⁹ or a group having the formula:




R^{18} is preferably H. R^{19} is preferably C_1 -alkylaryl. J is preferably -S-, -O- or -NR²¹-. where R²¹ is preferably H or methyl, more preferably H. L is preferably selected from the group consisting of:



5


L is more preferably



R^{24} and R^{25} are preferably independently selected from the group consisting of H, -O-R²⁶, -COOR²⁶, -CONR²⁶R²⁷ or -CF₃; more preferably H.

10

When L is:



then R^{22} is preferably H and R^{23} is preferably H.


When Z is:




15

then R^{20} is preferably -CF₃ or -CF₂CF₃.


In one preferred embodiment of the invention, s, k and p are 0; Y is O; R¹ and R² are H; and W is -C(O)-Z. This is also illustrated as a preferred group of compounds defined by the general structural formula II as:




A preferred embodiment of compounds of general structural formula II have the following stereochemistry:




5 In another preferred embodiment of the invention, s, k and p are 0; Y is O; X is H₂; R¹ and R² are H; and W is -C(O)-Z. This is also illustrated as a preferred group of compounds defined by the general structural formula III as:




10 A preferred embodiment of compounds of general structural formula III have the following stereochemistry:




In another preferred embodiment of the invention, s, k, p and m are 0; r is 3; Y is O; X is H₂; R¹ and R² are H; D is -SO₂-; E is a direct link; W is -C(O)-Z; and G is:



15 where R¹⁰, R¹², R¹³ and R¹⁴ are all H. This is also illustrated as a preferred group of compounds defined by the general structural formula IV as:



A preferred embodiment of compounds of general structural formula IV have the following stereochemistry:



5 This invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates and solvates of the compounds of formulas I, II, III and IV. In addition, the compounds of formulas I, II, III and IV can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates and solvates of such isomers and tautomers.

10 The compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.

15 A number of methods are useful for the preparation of the salts described above and are known to those skilled in the art. For example, the free acid or free base form of a compound of one of the formulas above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation,

distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.

This invention also encompasses prodrug derivatives of the compounds contained herein. The term "prodrug" refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug. Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under metabolic conditions. Prodrugs become the compounds of the invention which are pharmaceutically active *in vivo*, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, 1992). Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative. Moreover, the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.

The following structures are illustrative of the compounds of the present invention and are not intended to be limiting in any manner. It is to be noted that in the compounds of the invention, certain substituents are present between two other substituents. For example, Q is positioned between A-(CH₂)_m- and -(CH₂)_n-D-. Accordingly, substituents such as Q are illustrated below as having two "dangling" bonds, the bond on the left

representing a direct link to substituent A-(CH₂)_m- and the bond on the right representing a direct link to -(CH₂)_n-D-. Therefore, the general formula of A-(CH₂)_m-Q-(CH₂)_n-D- where Q is phenyl can be written as:



5

Q, a phenyl group, would then be written as follows in the tables below:





10

Other substituents in the table below may also be presented as having one or two similar "dangling" bonds. It is understood that these represent direct links to the adjacent substituent(s). It is also understood that the compounds illustrated below can exist as other isomers, and the isomeric form illustrated herein is not intended to be limiting in any manner.

The invention encompasses compounds of general structural formula V, where R¹ and R² are H; q is 1; p, k and s are 0; r is 3; E is a direct link; G is -NH-C(NH)NH₂; X and Y

are O; and W is




15


#	A	m	Q	n	D	K	t
1	H	0	-C6H5-	1	-SO ₂ -	CH ₃ O-	2
2	H	0	-C10H7-	0	-SO ₂ -	CH ₃ O-	2

#	A	m	Q	n	D	K	t
3		0	-N(cyclohexyl)-	2	direct link	CH ₃ O-	2
4		0	-phenyl-	1	-SO ₂ -	CH ₃ O-	2
5	H ₂ N-	1	-phenyl-	1	-CO-	CH ₃ O-	2
6	(CH ₃) ₃ -C-	0	-phenyl-	0	-SO ₂ -	CH ₃ O-	2
7	H ₃ C-	0	-N(cyclohexyl)-	0	-SO ₂ -	CH ₃ O-	2
8	H ₃ C-	0	-N(cyclopentyl)-	0	-SO ₂ -	CH ₃ O-	2
9		0	-phenyl-	0	-SO ₂ -	CH ₃ O-	2
10	H	0	-cyclohexyl-	2	-SO ₂ -	CH ₃ O-	2
11		0	direct link	3	-CO-	CH ₃ O-	2
12		0	-phenyl-	1	-SO ₂ -	CH ₃ O-	2
13		0	direct link	3	-CO-	CH ₃ O-	2
14		0	-phenyl-	1	direct link	CH ₃ O-	2
15	H	0		1	-SO ₂ -	CH ₃ CH ₂ O-	1
16	H	0		2	-CO-	CH ₃ CH ₂ O-	1

#	A	m	Q	n	D	K	t
17	H ₂ N-	0		1	-CO-	CH ₃ CH ₂ O-	1
18	HO-	0		2	-CO-	CH ₃ CH ₂ O-	1
19		1		1	-CO-	CH ₃ CH ₂ O-	1
20		0	-CH ₂ -C(CH ₃) ₂ -	0	-O-CO-	CH ₃ CH ₂ O-	1
21	H ₂ N-	0		2	-N(H)SO ₂ -	CH ₃ CH ₂ O-	1
22	H	0		2	-N(H)CO-	CH ₃ CH ₂ O-	1
23	H	0		2	-N(H)SO ₂ -	CH ₃ CH ₂ O-	1
24	H	0		1	-SO ₂ -	CH ₃ CH ₂ O-	1
25	H	0		0	-SO ₂ -	CH ₃ CH ₂ O-	1
26	H	0		0	-SO ₂ -	CH ₃ CH ₂ O-	1
27	H ₃ C-	0		0	-SO ₂ -	CH ₃ CH ₂ O-	1
28	H	0	direct link	0	direct link	CH ₃ CH ₂ O-	1

The invention encompasses compounds of general structural formula VI, where R¹ and R² are H; q is 1; p, k, s and m are 0; n is 2; r is 3; E is a direct link; A is H;






#	K	t
1	CH ₃ CH ₂ O-	2
2		2
3		2
4		2
5		
6		
7		2
8		2
9		2

The invention encompasses compounds of general structural formula VII, where R¹ and R² are H; q and n are 1; p, k, s and m are 0; n is 2; r is 3; E is a direct link; Q is

5 phenyl; A is H; G is -NH-C(NH)NH₂; W is ; D is -SO₂-; X is H₂; and Y is O:




#	K	t
1	HO-	2
2	cyclohexyl	2
3	CH ₃ O-	1
4	CH ₃ CH ₂ O-	1
5	HO-	1
6	cyclohexyl	1

The invention encompasses compounds of general structural formula VIII, where R¹ and R² are H; q is 1; p, k and m are 0; n is 1; D is -SO₂-; Q is phenyl; A is H; X is H₂; W

5

is , and Y is O:




#	r	E	s	G
1	3	direct link	0	
2	3	direct link	0	




	r	E	s	G
3	1		0	
4	1		0	
5	0		0	-NH ₂
6	2		0	H
7	2		0	-CH ₃
8	3		0	H
9	0		0	
10	4	direct link	0	-NH ₂
11	0		1	-NH ₂

The invention encompasses compounds of general structural formula IX, where R¹ and R² are H; A is H; p, k, s, m and n are 0; r is 3; q and t are 2; D is -SO₂-; X is H₂ and Y is O; E



is a direct link; K is OH-; Q is ; and G is -NH-C(NH)NH₂:




#	W
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	




#	W
15	
16	
17	

The invention encompasses compounds of general structural formula X, where A is H; p, k, s, m and n are 0; q is 1; r is 3; t is 2; D is -SO₂-; X is H₂; Y is O; E is a direct link;

Q is  ; W is  ; G is -N(CH₃)C(NH)NH₂; K is (CH₃)₃C(H)N(H)-:





5

#	R ¹	R ²
1	(CH ₃) ₂ CH ₂	H
2		H
3		H
4		H
5		H

#	R ¹	R ²
6		△

The invention encompasses compounds of general structural formula XI, where R¹ and R² are H; s and m are 0; r is 3; n is 1; t is 2; E is a direct link; G is -N(CH₃)-C(NH)NH₂;

5 A is  ; D is a direct link; Q is  ; W is  ; and K is (CH₃)₂-N-:



#	p	q	k	X	Y
1	0	1	0	H ₂	O
2	0	1	0	O	O
3	0	1	0	H ₂	O
4	0	1	0	H ₂	H ₂
5	0	2	0	H ₂	O
6	0	0	1	H ₂	O
7	0	3	0	H ₂	O
8	1	0	0	H ₂	O
9	0	1	0	H ₂	O
10	0	1	0	O	H ₂
11	1	0	0	H ₂	O

As mentioned above, the compounds of this invention find utility as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. Further, these compounds are useful for the treatment or prophylaxis of those diseases which involve the production and/or action of factor Xa/prothrombinase complex. This includes a number of thrombotic and prothrombotic states in which the coagulation cascade is activated which include but are not limited to, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion.

Accordingly, a method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprises administering to the mammal a therapeutically effective amount of a compound of this invention. In addition to the disease states noted above, other diseases treatable or preventable by the administration of compounds of this invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.

The compounds of the invention also find utility in a method for inhibiting the coagulation biological samples, which comprises the administration of a compound of the invention.

The compounds of the present invention may also be used in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of

5 this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects.

10 The compounds of this invention can be utilized *in vivo*, ordinarily in mammals such as primates. (e.g. humans), sheep, horses, cattle, pigs, dogs; cats, rats and mice, or *in vitro*.

15 The biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the *in vitro* protease activity assays and *in vivo* studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.

20 Diagnostic applications of the compounds of this invention will typically utilize formulations in the form of solutions or suspensions. In the management of thrombotic disorders the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles. Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.

Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.

Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods.

Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of this invention typically will be 3-11, more preferably 5-9 and most preferably 7-8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as orally, intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally, transdermally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, microencapsulation, oral dosage formulations and topical formulations.

such as ointments, drops and dermal patches. The compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.

5 The compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.

10 The compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of this invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidinone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block 15 copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.

20 Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.

25 Therapeutically effective dosages may be determined by either *in vitro* or *in vivo* methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will be influenced by the route of administration, the

therapeutic objectives and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each compound by methods well known in pharmacology. Accordingly, it may be necessary 5 for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be readily determined by one skilled in the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.

10 The compounds of the invention can be administered orally or parenterally in an effective amount within the dosage range of about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg and more preferably about 1 to 20 mg/kg on a regimen in a single or 2 to 4 divided daily doses and/or continuous infusion.

15 Typically, about 5 to 500 mg of a compound or mixture of compounds of this invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice. The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.

20 Typical adjuvants which may be incorporated into tablets, capsules and the like are binders such as acacia, corn starch or gelatin, and excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents. When a dosage form is a capsule, in addition to the above materials it may also contain 25 liquid carriers such as water, saline, or a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such

as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.

5

Preparation of the Disclosed Compounds

The compounds of the present invention may be synthesized by either solid or liquid phase methods described and referenced in standard textbooks, or by a combination of both methods. These methods are well known in the art. See, Bodanszky, "The Principles of Peptide Synthesis", Hafner, *et al.*, Eds., Springer-Verlag, Berlin, 1984.

10

Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.


Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated. The reaction products are isolated and purified by conventional methods, typically by solvent extraction into a compatible solvent. The products may be further purified by column chromatography or other appropriate methods. Most compounds are purified by reversed-phase HPLC and characterized by ion-spray mass spectrometry.

During the synthesis of these compounds, the functional groups of the amino acid derivatives used in these methods are protected by blocking groups to prevent side reactions during the coupling procedure. Examples of suitable blocking groups and their use are described in "The Peptides: Analysis, Synthesis, Biology", Academic Press, Vol. 3 (Gross, *et al.*, Eds., 1981) and Vol. 9 (1987), the disclosures of which are incorporated herein by reference.

25

The compounds of this invention may be preferably prepared by


- a) coupling the carboxylic acid of formula (a) to the amine of formula (b)



by the standard amide bond formation strategies, or

- b) where X is H₂, D is -SO₂- or -CO-, reacting the cyclic amine of formula (c) with the sulfonyl halide of formula (d) or with the carboxylic acid of formula of (e) through standard amide bond or sulfonamide formation strategies,

5



$$A-(CH_2)_m-Q-(CH_2)_n-SO_2-Cl \quad (d)$$

$$A-(CH_2)_m-Q-(CH_2)_n-COOH \quad (e)$$

The compounds of formula (b) wherein W is H can be prepared by the methods disclosed in WO 96/01338; WO 96/24609; Feng, et al., WO 96/31504; and WO 96/32110, the disclosures of which are incorporated herein by reference.

The compounds of formula (b) wherein W is a boron containing compound can be prepared by the methods disclosed in J. Org. Chem. 60:3717-3722 (1995) and de Nanteuil, *et al.*, EP 688,788, the disclosures of which are incorporated herein by reference.

The compounds of formula (b) wherein W is -C(O)-Z, where Z is H, may be prepared by the methods disclosed in WO 93/15756, *supra*; Vlasuk, *et al.*, WO 94/17817; Abelman, *et al.*, WO 94/21673; Webb, *et al.*, WO 94/08941; Veber, *et al.*, WO 94/25051; Levy, *et al.*, WO 95/35312; Semple, *et al.*, WO 95/35313; Abelman, *et al.*, WO 95/28420; and Abelman, *et al.*, WO 96/19493, the disclosures of which are incorporated herein by

reference.


The compounds of formula (b) wherein W is -C(O)-Z, where Z is -COOR¹⁸ or -CONR¹⁸R¹⁹, may be prepared by the methods disclosed in WO 94/25051, *supra*, WO 94/08941, *supra*, and WO 94/21673, *supra*, the disclosures of which are incorporated herein by reference.

5

The compounds of formula (b) wherein W is -C(O)-Z, where Z is -CF₃ or -CF₂CF₃, may be prepared by the methods disclosed in Schacht, *et al.*, GB 2287027, the disclosure of which is incorporated herein by reference.

10


The compounds of formula (b) wherein W is -C(O)-Z, where Z is:



and J is O, -SO- or -SO₂- can be readily synthesized by the methods disclosed in Costanzo, *et al.*, U.S. Pat. No. 5,523,308; Di Maio, *et al.*, WO 96/19483; U.S. Pat. No. 5,164,371; *J. Am. Chem. Soc.* 114: 1854-1863 (1992); *J. Med. Chem.* 38:76-85 (1995); and *J. Med. Chem.* 37:3492-3502 (1994). Lastly, fragments where J is -NR²¹-, where R²¹ is H, C₁₋₆alkyl or benzyl, can be synthesized by techniques illustrated in *J. Med. Chem.* 37:3492-3502 (1994). All of these references are incorporated herein by reference.

15

The compounds of formula (b) wherein W is -C(O)-Z, where Z is:



20

and U and V are the various substituents (-O-, -S-, -N-, -NH-) may be prepared by the methods disclosed in *J. Med. Chem.* 38: 1355-1371 (1995) and *J. Med. Chem.* 37: 2421-2436 (1994), the disclosures of which are incorporated herein by reference.


25

The starting compounds of formula (a), (c), (d) and (e) are either known compounds or can be produced by known methods (Heitsch, *et al.*, Canadian Patent No. 2,071,744; Sugihara, *et al.*, Canadian Patent No. 2,126,026; Baker, *et al.*, EP 365,992; U.S. Pat. No. 4,251,438; Carr, *et al.*, U.S. Pat. No. 4,341,698; Goldman, *et al.*, U.S. Pat. No. 5,120,718;

Biswanath, *et al.*, U.S. Pat. No. 5,164,388; Duggan, *et al.*, U.S. Pat. No. 5,281,585; Sugihara, *et al.*, U.S. Pat. No. 5,294,713; Bovy, *et al.*, WO 95/06038; WO 95/35308; *J. Chem. Soc. Perkin Trans. I* 1687-1689 (1989); and *Int. J. Peptide Protein Res.* 37:468-475 (1991)) or prepared by the methods shown in the following reaction formulae.

The following reaction schemes are more specific illustrations of the above reaction formulae. The chemical reactions described in each scheme can easily be modified and combined with other techniques that are well known in the art to produce other compounds within the scope of the invention.


10


Scheme I

15


Scheme II


20




Scheme III

10





5

Scheme IV


Without further elaboration, it is believed that one skilled in the art can utilize the

present invention to its fullest extent. Therefore, the following preferred specific embodiments are to be construed as merely illustrative and do not limit the remainder of the disclosure in any way whatsoever.

5

Preparation of:

Example 1



10

15


To a suspension of Boc-Arg(Tos)-OH (2 g, 4.7 mmol) in DMF (20 mL) at 0°C was added MeNHOMe•HCl (1 g, 10.3 mmol), DIEA (6 mL) and BOP (2.5 g, 5.6 mmol). The solution was stirred at 0°C for 10 hours. DMF was evaporated by vacuum. The oily residue was dissolved in EtOAc (200 mL) and water (20 mL). The organic layer was washed with sat. NaHCO₃, water (20 mL), 1 M HCl (10 mL) and sat. NaCl (2 X 20 mL). The organic layer was dried over MgSO₄, filtered and evaporated to give a suspension. The suspension was filtered, and the solid was washed with cold EtOAc (10 mL) and dried to give Boc-Arg(Tos)-N(Me)OMe, shown above, (1.5 g, 70 % yield).

FAB-MS (M+H)⁺ = 472

20

Preparation of:

Example 2




To a solution of thiazole (2.5 g, 29 mmol) in THF (25 mL) at -78°C was added n-BuLi (1.6 M in hexane, 19 mL) dropwise. The mixture was stirred for 30 minutes. Then a

solution of Boc-Arg(Tos)-N(Me)OMe, from Example 1, (1.7 g, 3.6 mmol) in THF (50 mL) was added to the lithiothiazole mixture at -78°C. The solution was stirred for 2 hours. 1M HCl (30 mL) was added to the reaction mixture and warmed to room temperature. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with sat. NaCl (30 mL), dried over MgSO₄, filtered and evaporated. The crude oily residue was purified by flash column chromatography over SiO₂ (50% EtOAc in CH₂Cl₂) to give Boc-Arg(Tos)-thiazole, shown above, (1.5 g, 84% yield) as a powder.

DCI -MS (M+H)⁺ = 496

10

Preparation of:

Example 3


15

To a solution of Boc-Arg(Tos)-thiazole from Example 2, (300 mg, 0.6 mmol) in CH₂Cl₂ (10 mL) at 0°C, was added TFA (10 mL). The solution was stirred at 0°C for 2 hours. The solvent and excess TFA were evaporated to give an oily residue which was used directly without further purification.

20

Example 4

Part 1-Preparation of N-(2,2-dimethoxyethyl)glycine tert-butyl ester:




To a mixture of 2,2-dimethoxyethylamine (15 g, 143 mmol), anhydrous potassium carbonate (20 g, 145 mmol) and DMF (140 mL) was added tert-butyl bromoacetate (11.5 mL, 71.2 mmol). After stirring at room temperature for 2 hours, another portion of tert-butyl bromoacetate (11.5 mL, 71.2 mmol) was added to the mixture, which was stirred

overnight at room temperature. To the reaction mixture was added ice-water (140 mL). The mixture was extracted with EtOAc. The organic layer was washed with sat. NaCl, dried over Na₂SO₄, filtered and evaporated. The residue was subjected to distillation under reduced pressure to give the title compound as a colorless oil (6.61 g).

5 ES-MS (M+H)⁺ = 220.0

Part 2-Preparation of methyl (4R)-4-{[(benzyloxy)carbonyl]amino}-5-[[2-(tert-butoxy)-2-oxoethyl](2,2-dimethoxyethyl)amino]-5-oxopentanoate:




10 To a suspension of Cbz-D-Glu(OMe) (2.97 g, 10.07 mmol) in DMF (7.5 mL) at 0°C was added DIEA (4.40 mL, 25.17 mmol), the compound of Part 1 (3.20 g, 14.66 mmol) and BOP (5.57 g, 12.60 mmol). The solution was warmed up to room temperature and stirred at room temperature for 4 hours. The reaction mixture was dissolved in EtOAc and water. The organic layer was washed with sat. NaHCO₃, 1 N HCl and sat. NaCl, dried over MgSO₄, filtered and concentrated *in vacuo*. Flash chromatography on silica gel with 30% EtOAc/Hexane as eluent afforded the title compound (5.03 g, quantitative yield).

15

ES-MS (M+H)⁺ = 497.4

20 Part 3-Preparation of benzyl (2R)-4-[2-(tert-butoxy)-2-oxoethyl]-2-(3-methoxy-3-oxopropyl)-3-oxo-1,2,3,4-tetrahydro-1-pyrazinecarboxylate:




A solution of the compound from Part 2 (1.50 g, 3.19 mmol) and pTsOH (69.9 mg, 0.37 mmol) in toluene (20 mL) was heated to reflux for 5 hours. The reaction mixture was

cooled and concentrated *in vacuo*. The residue was dissolved in EtOAc and the resulting solution was washed with sat. NaHSO₄, sat. NaCl, dried over MgSO₄, filtered, and solvent evaporated under reduced pressure. Flash column chromatography on silica gel with 30 % ethyl acetate/hexane as eluent afforded the title compound (1.19 g, 86.2 % yield).

5

ES-MS (M+H)⁺ = 433.4

Part 4-Preparation of methyl 3-((2R)-4-[2-(tert-butoxy)-2-oxoethyl]-3-oxohexahydro-2-pyrazinyl)propanoate:




10

To a solution of the compound of Part 3 (4.53 g, 10.48 mmol) in absolute ethanol (100 mL) was added 10% Pd/C (0.45 g) and one drop of concentrated HCl. The mixture was stirred vigorously for 24 hours in hydrogen streams. The catalyst was filtered off and the filtrate was evaporated *in vacuo* to afford the title compound (2.74 g, 89.5% yield).

15

ES-MS (M+H)⁺ = 301.3

Part 5-Preparation of methyl-3-((2R)-1-(benzylsulfonyl)-4-[2-(tert-butoxy)-2-oxoethyl]-3-oxohexahydro-2-pyrazinyl)propanoate:




20

To a solution of the compound of Part 4 (1.80 mmol) and DIEA (1.74 ml, 10.0 mmol) in CH₂Cl₂ (10 mL) at -78°C, was added α-toluenesulfonyl chloride (0.76 g, 4.0 mmol). The mixture was stirred at -78°C for one and one-half hours. The solution was warmed up to room temperature and stirred at room temperature for 24 hours. The solvent was

evaporated *in vacuo*. The residue was dissolved in EtOAc and H₂O. The organic layer was washed with water, sat. NaHCO₃, sat. NaCl, 1 N HCl, dried over MgSO₄ and evaporated. The residue was purified by RP-HPLC to afford the title compound (0.77 g. 93.9% yield).

5 ES-MS (M+H)⁺ = 455.2

Part 6-Preparation of methyl 3-[(2R)-1-(benzenesulfonyl)-4-(2-{{(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino}-2-oxoethyl)-3-oxohexahydro-2-pyrazinyl]propanoate:



10


The compound of Part 5 (770 mg, 1.69 mmol) was treated with 50% TFA/ CH₂Cl₂ (10 mL) at 0°C and the mixture was stirred for 3 hours at 0°C. It was then evaporated to afford a viscous gum. This (200mg, 0.5 mmol) was dissolved in DMF (1.0 mL) and cooled to 0°C. The solution was neutralized with DIEA (0.22 mL) followed by addition of the compound of Example 3 (0.7mmol) and coupling reagent BOP (250 mg, 0.56 mmol). The solution was stirred for 1 hour at 0°C and overnight at room temperature. The reaction mixture was concentrated *in vacuo*. The residue was purified by RP-HPLC to afford the title compound (207 mg, 54.7% yield).

15

ES-MS (M+H)⁺ = 776.2

20

Part 7-Preparation of methyl 3-[(2R)-4-(2-{{(1S)-4-{{[amino(imino)methyl]amino}-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino}-2-oxoethyl)-1-(benzylsulfonyl)-3-oxohexahydro-2-pyrazinyl]propanoate (an isomer of Compound V(1)):



The compound of Part 6 (50 mg, 0.06 mmol), anisole (0.5 mL) and ethyl methyl sulfide (two drops) were placed in HF-cleavage vessel and cooled under liquid N₂. HF (5 mL) was condensed and the mixture was stirred at 0-5°C for one hour. HF was removed under vacuum to give a gum-like residue. The residue was triturated with Et₂O and the solvent decanted. The gum residue was dissolved in 0.1% aq. TFA and lyophilized to give a powder which was purified by RP-HPLC to give the title compound as a white powder (39.49 mg, 98.7% yield).


5

ES-MS (M+H)⁺ = 622.2

10

Example 5

Part 1-Preparation of 3-[(2R)-1-(benzenesulfonyl)-4-(2-[(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino)-2-oxoethyl]-3-oxohexahydro-2-pyrazinyl]propanoic acid:




15

20

A solution of the compound of Part 6 of Example 4 (210 mg, 0.27 mmol) in THF (6.0 mL) was treated with 2 N HCl (8 mL). The solution was stirred at room temperature for 60 hours. The organic solvent was evaporated *in vacuo*. The aqueous layer was extracted with EtOAc. The organic layer was washed with sat. NaCl, dried over MgSO₄, filtered, and concentrated under reduced pressure. RP-HPLC purification followed by lyophilization afforded the title compound (103.8 mg, 50.4 % yield).

ES-MS ($M+H$)⁺ = 762.3

Part 2-Preparation of 3-[(2R)-4-(2-{{(1S)-4-({[amino(imino)methyl]amino}-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino}-2-oxoethyl)-1-benzylsulfonyl-3-oxohexahydro-2-pyraziny]propanoic acid (an isomer of Compound VII(1)):




The title compound was synthesized by the method of Part 7 of Example 4 starting with the compound of Part 1 and HF.

ES-MS ($M+H$)⁺ = 608.1

10

Example 6

Part 1-Preparation of N1-[(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]-2-[(3R)-4-(benzylsulfonyl)-2-oxo-3-(3-oxo-3-piperidinopropyl)hexahydro-1-pyrazinyl]acetamide:




15

The compound of Part 1 of Example 5 (55 mg, 0.07 mmol) was dissolved in DMF (1 mL) and cooled to 0°C. The solution was neutralized with DIEA (31.4 μ L, 0.18 mmol) followed by addition of BOP (36.7 mg, 0.08 mmol) and piperidine (10.71 μ L, 0.11 mmol). The solution was warmed up to room temperature and stirred for 3 hours. DMF was removed under reduced pressure. RP-HPLC purification and subsequent

lyophilization gave the title compound (50.5 mg, 84.4% yield).

ES-MS ($M+H$)⁺ = 829.4

Part 2-Preparation of N1-[(1S)-4-{{[amino(imino)methyl]amino}-1-(1,3-thiazol-2-ylcarbonyl)butyl]-2-[(3R)-4-(benzylsulfonyl)-2-oxo-3-(3-oxo-3-piperidinopropyl)-hexahydro-1-pyrazinyl]acetamide (an isomer of Compound VII(2)):




The title compound was synthesized by the method of Part 7 of Example 4 starting with the compound of Part 1 and HF. (26.39 mg, 76.7% yield).

ES-MS ($M+H$)⁺ = 675.3

Example 7

Preparation of methyl 3-[(2S)-4-(2-{{(1S)-4-{{[amino(imino)methyl]amino}-1-(1,3-thiazol-2-ylcarbonyl)butyl}amino}allyl)-1-(benzylsulfonyl)-3-oxohexahydro-2-pyrazinyl]propanoate (an isomer of Compound V(1)):




The title compound was synthesized by the method of Example 4 starting with the N-(2,2-dimethoxyethyl)glycine tert-butyl ester (Part 1 of Example 4) and Cbz-Glu(OMe)-OH.

ES-MS ($M+H$)⁺ = 621.9

Example 8

Part 1-Preparation of benzyl (2S)-4-[2-(*tert*-butoxy)-2-oxoethyl]-2-(2-methoxy-2-oxoethyl)-3-oxo-1,2,3,4-tetrahydro-1-pyrazinecarboxylate:




5

To a solution of the compound of Part 1 of Example 4 (1.92 g, 8.77 mmol) and Cbz-Asp(OMe)-OH (2.47 g, 8.77 mmol) in CH₂Cl₂ (20 mL) was added, while stirring under ice-cooling, EDC (1.93 g, 10.1 mmol). The mixture was stirred for 10 min. under ice-cooling, then for 50 min. at room temperature. To the reaction mixture were added water (30 mL) and 5% aqueous solution of KHSO₄ (10 mL). The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂ (20 mL). The organic layers were combined, washed with water and dried over Na₂SO₄, followed by evaporation of the solvent under reduced pressure. The residue was dissolved in toluene (50 mL), to which was added p-toluenesulfonic acid (334 mg, 1.75 mmol), followed by stirring for 20 hrs. at 15 70-75°C. The reaction mixture was cooled, washed with sat. NaHCO₃, dried over Na₂SO₄, and the solvent was evaporated under reduced pressure. The residue was chromatographed on silica gel (40 g) with hexane/ethyl acetate (3:1) as eluent to afford the title compound (1.99 g, 54% yield).

ES-MS (M+H)⁺ = 419.0

20

Part 2-Preparation of methyl-2-{(2S)-4-[2-(*tert*-butoxy)-2-oxoethyl]-3-oxohexahydro-2-pyrazinyl}acetate:




To a solution of the compound of Part 1 (1.9 g, 4.5 mmol) in ethyl acetate (40 mL)

was added 10% Pd/C (0.5 g). The mixture was stirred vigorously for 24 hours in hydrogen streams. The catalyst was filtered off and the filtrate was evaporated in vacuo to afford the title compound (1.29 g, 100% yield).

ES-MS (M+H)⁺ = 287.1

5


Part 3-Preparation of methyl-2-((2S)-1-(benzylsulfonyl)-4-[2-(*tert*-butoxy)-2-oxoethyl]-3-oxohexahydro-2-pyrazinyl}acetate:



To a solution of the compound of Part 2 (0.75 g, 2.63 mmol) and DIEA (0.91 mL, 5.25 mmol) in CH₂Cl₂ (10 mL) at -78°C, was added α-toluenesulfonyl chloride (0.6 g, 3.15 mmol). The mixture was stirred at -78°C for one hour, and stirred at room temperature for two and one-half hours and evaporated *in vacuo*. The residue was dissolved in EtOAc and H₂O. The organic layer was washed with water, sat. NaHCO₃, sat. NaCl, 1M KHSO₄, dried over Na₂SO₄ and evaporated to give the title compound as a solid (954 mg, 82.5% yield).

15
ES-MS (M+H)⁺ = 441.2

Part 4-Preparation of methyl-2-[(2S)-1-(benzenesulfonyl)-4-(2-[(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino)-2-oxoethyl]-3-oxohexahydro-2-pyrazinyl]acetate:



The compound of Part 3 (532.8 mg, 1.21 mmol) was treated with 50% TFA/CH₂Cl₂


(4 mL) at 0°C and the mixture was stirred for 2 hours at 0°C. It was then evaporated to afford a viscous gum. This was dissolved in DMF (8 mL) and cooled to 0°C. The solution was neutralized with DIEA (1 mL) followed by addition of the compound of Example 3 (1mmol) and coupling reagent BOP (487 mg, 1.1 mmol). The solution was stirred for 2-3 hours at 0°C and overnight at room temperature. The reaction mixture was diluted in a mixture of EtOAc/H₂O (50 mL:10 mL). The organic layer was washed with sat. NaHCO₃, sat. NaCl, dried over MgSO₄, filtered and the solvent evaporated to give the title compound (660 m g, 71.7% yield).

5

ES-MS (M+H)⁺ = 762.2.

10

Part 5-Preparation of methyl-2-[(2S)-4-[(1S)-4-amino(imino)methylamino-1-(1,3-thiazol-2-ylcarbonyl)butylcarbamoylmethyl]-1-benzylsulfonyl-3-oxohexahydro-2-pyrazinyl} acetate (an isomer of Compound VII(3)):



15


The compound of Part 4 (313 mg, 0.41 mmol), anisole (1 mL) and ethyl methyl sulfide (two drops) were placed in an HF-cleavage vessel and cooled under liquid N₂. HF (10 mL) was then condensed and the mixture was stirred at -10°C for 30 minutes and 0°C for 30 minutes. HF was removed under vacuum to give a gum-like residue. The residue was triturated with 50%Et₂O in hexane (20 mL) and the solvent removed by filtration. The gum residue was dissolved in 0.1% aq. TFA (15 mL) and filtered through the above sintered funnel. The filtrate was lyophilized to give a powder which is purified by RP-HPLC to give the title compound as a white powder.

20

ES-MS (M+H)⁺ = 608.3.

Example 9

Preparation of methyl 2-((2R)-4-[(1S)-4-amino(imino)methylamino]-1-(1,3-thiazol-2-ylcarbonyl)butylcarbamoylmethyl]-1-benzylsulfonyl-3-oxohexahydro-2-pyrazinyacetate (an isomer of Compound VII(3)):



5


The title compound was synthesized by the method of Example 8 starting with the N-(2,2-dimethoxyethyl)glycine tert-butyl ester (Part 1 of Example 4) and Cbz-D-Asp(OMe)-OH.

ES-MS (M+H)⁺ = 608.1.

10

Example 10

Part 1-Preparation of ethyl 2-[(2S)-1-(benzenesulfonyl)-4-(2-[(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino)-2-oxoethyl]-3-oxohexahydro-2-pyrazinylacetate:




15

The title compound was synthesized by the method of Part 4 of Example 8 starting with the N-(2,2-dimethoxyethyl)glycine tert-butyl ester (Part 1 of Example 4) and Cbz-Asp(OEt)-OH.

ES-MS (M+H)⁺ = 798

20

Part 2-Preparation of ethyl 2-[(2S)-4-[(1S)-4-amino(imino)methylamino-1-(1,3-thiazol-2-ylcarbonyl)butylcarbamoylmethyl]-1-benzylsulfonyl-3-oxohexahydro-2-pyrazinyl}acetate (an isomer of Compound VII(4)):




5 The title compound was synthesized by the method of Part 5 of Example 8 starting with the compound of Part 1 and HF.

ES-MS (M+H)⁺ = 622.1

Example 11


10 Part 1-Preparation of ethyl 2-[(2R)-1-(benzenesulfonyl)-4-(2-[(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino)-2-oxoethyl]-3-oxohexahydro-2-pyrazinyl]acetate:



15 The title compound was synthesized by the method of Part 4 of Example 8 starting with the N-(2,2-dimethoxyethyl)glycine tert-butyl ester (Part 1 of Example 4) and Cbz-D-Asp(OEt)-OH.

ES-MS (M+H)⁺ = 798

20 Part 2-Preparation of ethyl 2-[(2R)-4-[(1S)-4-amino(imino)methylamino-1-(1,3-thiazol-2-ylcarbonyl)butylcarbamoylmethyl]-1-benzylsulfonyl-3-oxohexahydro-2-pyrazinyl]acetate (an isomer of Compound VII(4)):




The title compound was synthesized by the method of Part 5 of Example 8 starting with the compound of Part 1 and HF.

ES-MS ($\text{M}+\text{H})^+ = 622.1$

5

Example 12

Part 1-Preparation of 2-[(2S)-1-(benzenesulfonyl)-4-(2-[(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino)-2-oxoethyl)-3-oxohexahydro-2-pyrazinyl]acetic acid:



10

15


A solution of the compound of Part 1 of Example 10 (155 mg, 0.2 mmol) in THF (2 mL) was treated with LiOH (17 mg, 0.4 mmol) and water (0.5 mL). The mixture was stirred at room temperature for two and one-half hours. The organic solvent was evaporated in vacuo. The aqueous layer was extracted with EtOAc to remove organic impurities and acidified to pH 2-3 with 2N aq HCl at 0°C. The acidified aqueous layer was extracted with EtOAc and the organic layer was dried over Na_2SO_4 and evaporated to give the title compound as a white solid (80mg).

ES-MS ($\text{M}+\text{H})^+ = 748$

20

Part 2-Preparation of 2-[(2S)-4-[(1S)-4-amino(imino)methylamino]-1-(1,3-thiazol-2-ylcarbonyl)butylcarbamoylmethyl]-1-benzylsulfonyl-3-oxohexahydro-2-pyrazinyl]acetic

acid (an isomer of Compound VII(5)):




The title compound was synthesized by the method of Part 5 of Example 8 starting with the compound of Part 1 and HF.

5 ES-MS (M+H)⁺ = 594.0

Example 13


Part 1-Preparation of 2-[(2R)-1-(benzenesulfonyl)-4-(2-{{(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino}-2-oxoethyl)-3-oxohexahydro-2-pyrazinyl]acetic acid:



The title compound was synthesized by the method of Part 1 of Example 12 starting with the compound of Part 1 of Example 11.

15 ES-MS (M+H)⁺ = 748

Part 2-Preparation of 2-{{(2R)-4-[(1S)-4-amino(imino)methylamino]-1-(1,3-thiazol-2-ylcarbonyl)butylcarbamoylmethyl]-1-benzylsulfonyl-3-oxohexahydro-2-pyrazinyl}acetic acid (an isomer of Compound VII(5)):




The title compound was synthesized by the method of Part 5 of Example 8 starting with the compound of Part 1 and HF.

ES-MS ($\text{M}+\text{H})^+ = 594.2$.

5

Example 14

Part 1-Preparation of N1-[(1*S*)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]-2-[(3*S*)-4-(benzylsulfonyl)-2-oxo-3-(2-oxo-2-piperidinoethyl)hexahydro-1-pyrazinyl]acetamide:




10

The compound of Part 1 of Example 12 (271 mg, 0.36 mmol) was dissolved in DMF (5 mL) and cooled to 0°C. The solution was neutralized with DIEA (0.13 mL, 0.72 mmol) followed by addition of BOP (161 mg, 0.36 mmol) and piperidine (37 mg, 0.44 mmol). The solution was stirred for 2-3 hours at 0°C and overnight at room temperature. The reaction mixture was diluted in a mixture of EtOAc/H₂O (20 mL:10 mL). The organic layer was washed with sat. NaHCO₃, sat. NaCl, dried over MgSO₄, filtered and the solvent evaporated to give the title compound (162 m g, 55% yield).

15

ES-MS ($\text{M}+\text{H})^+ = 815.2$

Part 2-Preparation of N1-[(1S)-4-amino(imino)methylamino-1-(1,3-thiazol-2-ylcarbonyl)butyl]-2-[(3S)-4-benzylsulfonyl-2-oxo-3-(2-oxo-2-piperidinoethyl)-hexahydro-1-pyrazinyl]acetamide (an isomer of Compound VII(6)):




5 The title compound was synthesized by the method of Part 5 of Example 8 starting with the compound of Part 1 and HF.

ES-MS ($\text{M}+\text{H})^+ = 661.3$.

Example 15

10 Part 1-Preparation of N1-[(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}-methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]-2-[(3R)-4-(benzylsulfonyl)-2-oxo-3-(2-oxo-2-piperidinoethyl)-hexahydro-1-pyrazinyl]acetamide:




15 The title compound was synthesized by the method of Part 1 of Example 14 starting with the compound of Part 1 of Example 13.

ES-MS ($\text{M}+\text{H})^+ = 815.2$

Part 2-Preparation of N1-[(1S)-4-amino(imino)methylamino-1-(1,3-thiazol-2-

ylcarbonylbutyl]-2-[(3R)-4-benzylsulfonyl-2-oxo-3-(2-oxo-2-piperidinoethyl)-hexahydro-1-pyrazinyl]acetamide (an isomer of Compound VII(6)):




The title compound was synthesized by the method of Part 5 of Example 8 starting
5 with the compound of Part 1 and HF.

ES-MS ($M+H$)⁺ = 661.3

Example 16

Part 1-Preparation of benzyl 2-(2-ethoxy-2-oxoethyl)-3-oxo-1-piperazinecarboxylate:



10


Ethyl 3-oxopiperazine-2-acetate (372 mg, 2 mmol) was dissolved in DMF (10 mL), triethylamine (0.56 mL, 4 mmol) and N-(benzyloxycarbonyloxy)succinimide (548 mg, 2.2 mmol) were added. The mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate and the organic layer was washed with water, sat. NaHCO₃ solution and sat. NaCl. It was then dried over anhydrous Na₂SO₄, filtered and evaporated to give the title compound (454 mg, 71% yield).

15

ES-MS ($M+H$)⁺ = 321.0

Part 2-Preparation of benzyl 4-[2-(tert-butoxyl)-2-oxoethyl]-2-(2-ethoxy-2-oxoethyl)-3-oxo-1-piperazinecarboxylate:

20




To a stirred solution of the compound of Part 1 (400 mg, 1.25 mmol) in THF (10 mL) at -78°C was added LiN(TMS)₂ (1M in THF, 1.375 mL, 1.375 mmol). The mixture was stirred at -78°C for 30 minutes. t-Butyl bromoacetate (0.37 mL, 2.5 mmol) was then added to the reaction mixture. The reaction was stirred at room temperature overnight, quenched with HOAc (0.2 mL) and diluted with EtOAc. The organic layer was washed with water, sat. NaCl, dried with Na₂SO₄ and concentrated to give the title compound (0.84g) as an oil.

DCI-MS (M+H)⁺ = 435.

10


Part 3-Preparation of 2-[4-[(benzyloxy)carbonyl]-3-(2-ethoxy-2-oxoethyl-2-oxopiperazino]acetic acid:



To the compound of Part 2 (1.25 mmol) in methylene chloride (5 mL) at 0°C, was added TFA (5 mL) dropwise. The reaction was stirred at room temperature for 5 hours and concentrated to give the title compound as a brownish oil.

DCI-MS (M+1)⁺ = 379.

20 **Part 4-Preparation of benzyl 2-(2-ethoxy-2-oxoethyl)-4-(2-{{(1S)-4-[(imino{[(4-methylphenyl)sulfonyl]amino}methyl)amino]-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino}-2-oxoethyl)-3-oxo-1-piperazinecarboxylate:**




The title compound was synthesized by the method of Part 4 of Example 8 starting with the compound of Part 3 and the compound of Example 3.

ES-MS ($M+Na$)⁺ = 778.

5

Part 5-Preparation of ethyl 2-[4-(2-{[(1S)-4-({[amino(imino)methyl]amino}-1-(1,3-thiazol-2-ylcarbonyl)butyl]amino}-2-oxoethyl)-3-oxo-2-piperazinyl]acetate (Compound V(28)):



10

The title compound was synthesized by the method of Part 5 of Example 8 starting with the compound of Part 4 and HF. ES-MS ($M+H$)⁺ = 468.3

Example 17

(Determination of IC₅₀)

15

The compounds of the present invention are first dissolved in a buffer to give solutions containing concentrations such that assay concentrations range from 0-100 μ M. In assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate would be added to a solution containing a test compound and the enzyme of interest and the residual catalytic activity of that enzyme would then be determined spectrophotometrically.

20

The IC₅₀ of a compound is determined from the substrate turnover. The IC₅₀ is the concentration of test compound giving 50% inhibition of the substrate turnover.

Preferred compounds of the invention desirably have an IC₅₀ of less than 500 nM in the factor Xa assay, preferably less than 200 nM, and more preferably less than 100 nM.

5 Preferred compounds of the invention desirably have an IC₅₀ of less than 4.0 μM in the prothrombinase assay, preferably less than 200 nM, and more preferably less than 10 nM. Preferred compounds of the invention desirably have an IC₅₀ of greater than 1.0 μM in the thrombin assay, preferably greater than 10.0 μM, and more preferably greater than 100.0 μM.

10 Amidolytic Assays for determining protease inhibition activity

Factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris HCl buffer, pH 7.5, containing 0.15 M NaCl. The rates of hydrolysis of the para-nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with the test compound for 5 minutes at room temperature are determined using a Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroanilide.

15 The prothrombinase inhibition assay is performed in a plasma free system with modifications to the method as described by Sinha, *et al.*, Thromb. Res., 75:427-436 (1994). The activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH. The assay consists of a 5 minute preincubation of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 μM) in 20 mM Tris HCl buffer, pH 7.5, containing 0.15 M NaCl, 5 mM CaCl₂ and 0.1% bovine serum albumin. Aliquots from the complex-test compound mixture are added to prothrombin (1 nM) and Chromozym TH (0.1 mM). The rate of substrate cleavage is monitored at 405 nm for two minutes. Several concentrations of a given test compound are assayed in duplicate.

A standard curve of thrombin generation by an equivalent amount of untreated complex is then used for determination of percent inhibition.

The compounds of the invention exhibited inhibitory activity in the Factor Xa assay described above. Typical IC₅₀ values were within the range of 2 μM to 3 nM.

5

Example 18

The antithrombotic efficacy of the compounds of this invention can readily be evaluated using a series of studies in rabbits, as described below. These studies are also useful in evaluating a compounds effects on hemostasis and its the hematological parameters.

10

Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis

A rabbit deep vein thrombosis model as described by Hollenbach, *et al.*, Thromb Haemost. 71:357-362 (1994), is used to determine the *in vivo* antithrombotic activity of the compounds of the present invention. Rabbits are anesthetized with I.M. injections of Ketamine, Xylazine, and Acepromazine cocktail.


A standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit. A non-occlusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is then used as a measure of the antithrombotic activity of the compound being evaluated. Test agents or control saline are administered through a marginal ear vein catheter. A femoral vein catheter is used for blood sampling prior to and during steady state infusion of the compound being evaluated. Initiation of thrombus formation will begin immediately after advancement of the cotton thread apparatus into the central venous circulation. The compounds being evaluated are administered from time=30 minutes to time=150 minutes at which point the experiment is terminated. The rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are then analyzed for changes in hematological and coagulation parameters.

Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention.

5 Accordingly, the invention is limited only by the following claims.

What is claimed is:

I. A compound having the formula:



5 Wherein:

R^1 is selected from the group consisting of H, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₃alkylaryl, C₁₋₃alkyl-C₃₋₈cycloalkyl and aryl and R^2 is H, or R^1 and R^2 are taken together to form a carbocyclic ring;

m is an integer from 0-2;

10 n is an integer from 0-6;

k is an integer from 0-1;

p is an integer from 0-1;

a is an integer from 0-3;


r is an integer from 0-4;

s is an integer from 0-1:

Journal of Safety 64

— 5 —

It is selected from the group $\{M^{\alpha\beta}\}_{\alpha,\beta=1}^{n-2}$.



where R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of H, -OH, C₁₋₆alkyl, aryl and C₁₋₄alkylaryl; R⁷ is selected from the group consisting of H, C₁₋₆alkyl,

aryl and C_{1-4} alkylaryl, or can be taken together with R^5 or R^6 to form a 5-6 membered ring; and R^8 is selected from the group consisting of H, C_{1-6} alkyl, aryl and C_{1-4} alkylaryl, or can be taken together with R^6 to form a 5-6 membered ring:

Q is selected from the group consisting of a direct link, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkenyl, C_{1-6} alkenylaryl, aryl, and a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;

D is selected from the group consisting of a direct link, -CO-, -SO₂-, -O-CO-, -NR⁹-SO₂- and -NR⁹-CO-, where R⁹ is selected from the group consisting of H, -OH, C_{1-6} alkyl, aryl and C_{1-4} alkylaryl;


10 X is O or H₂;

Y is O or H₂;

K is selected from the group consisting of R^{28} O- and $R^{29}R^{30}N-$, where R^{28} , R^{29} and R^{30} are independently selected from the group consisting of H, C_{1-6} alkyl, C_{0-3} alkylaryl, C_{0-3} alkyl C_{3-8} cycloalkyl, C_{0-3} alkylheterocycle; and where R^{29} and R^{30} can be taken together to form a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;

E is selected from the group consisting of a direct link, C_{3-8} cycloalkyl, aryl, and a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;


20 G is selected from the group consisting of R^{10} , -NR¹⁰R¹¹,



where R^{10} , R^{11} , R^{12} and R^{13} are independently selected from the group consisting of H, -OH, C_{1-6} alkyl, aryl and C_{1-4} alkylaryl; R^{14} is selected from the group consisting of H, C_{1-6} alkyl, aryl and C_{1-4} alkylaryl, or can be taken together with R^{12} or R^{13} to form a 5-6


membered ring; and R¹⁵ is selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₆alkylaryl, or can be taken together with R¹³ to form a 5-6 membered ring; with the proviso that when G is R¹⁰, then E must contain at least one N atom;

W is selected from the group consisting of H.



5

where R¹⁶ and R¹⁷ are independently selected from the group consisting of H, C₁₋₃alkyl and aryl; and Z is selected from the group consisting of H, -COOR¹⁸, -CONR¹⁸R¹⁹, -CF₃, -CF₂CF₃ and a group having the formula:



10

where:

R¹⁸ and R¹⁹ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl and C₁₋₆alkylaryl;

U is selected from the group consisting of -O-, -S-, -N- and -NH-; and


V is selected from the group consisting of -O-, -S-, -N- and -NH-; with the proviso that at least one of U or V is -N- or -NH-;

15 R²⁰ is selected from the group consisting of H, C₁₋₆alkyl, C₂₋₆alkenyl, C₀₋₆alkylaryl, C₁₋₆alkenylaryl, C₀₋₆alkylheterocyclo, C₂₋₆alkenylheterocyclo, -CF₃ and -CF₂CF₃.

J is selected from the group consisting of -S-, -SO-, -SO₂-, -O- and -NR²¹-; where R²¹ is selected from the group consisting of H, C₁₋₆alkyl and benzyl; and

20

L is selected from the group consisting of:



and

a C₆₋₁₀ heterocyclic ring system substituted by R²⁴ and R²⁵ and containing 1-4

heteroatoms selected from N, S and O;

where d is an integer from 0-2;

5 R²² and R²³ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl, C₁₋₆alkylaryl, -COOR²⁶, -CONR²⁶R²⁷, -CN and -CF₃;

R²⁴ and R²⁵ are independently selected from the group consisting of H, C₁₋₆alkyl, aryl, C₁₋₆alkylaryl, C₁₋₄alkyloxy, halogen, -NO₂, -NR²⁶R²⁷, -NR²⁶COR²⁷, -OR²⁶, -OCOR²⁶, -COOR²⁶, -CONR²⁶R²⁷, -CN, -CF₃, -SO₂NR²⁶R²⁷ and C₁₋₆alkyl-OR²⁶; and

10 R²⁶ and R²⁷ are independently selected from the group consisting of H, C₁₋₆alkyl, C₁₋₃alkylaryl and aryl; and all pharmaceutically acceptable salts and optical isomers thereof.

15 2. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and the compound of claim 1.

20 3. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of the compound of claim 1.

25 4. The method of claim 3, wherein the condition is selected from the group consisting of: the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the

5 prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. deep venous thrombosis. pulmonary embolism. myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion. occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature and disseminated intravascular coagulopathy.

5. A method for inhibiting the coagulation of biological samples, comprising the administration of the compound of claim 1.

10

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/07159

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K5/ A61K38/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 09133 A (SMITHKLINE BEECHAM CORP) 13 May 1993 whole document, esp. examples, claims, page 24, line 20 to page 25, line 15 ---	1-5
Y	WO 96 40744 A (COR THERAPEUTICS INC ; MARLOWE CHARLES K (US); SCARBOROUGH ROBERT M) 19 December 1996 whole document, esp. page 29, lines 17-20, examples 14,15, abstract ---	1-5
A	WO 95 35313 A (CORVAS INT INC ; SEMPLE JOSEPH E (US); LEVY ODILE E (US); NUTT RUTH) 28 December 1995 whole document, especially examples and pages 86/87 ---	1-5 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

26 June 1998

03/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kronester-Frei, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/07159

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 19491 A (IAF BIOCHEM INT ;GILLARD JOHN (CA); DIMAIO JOHN (CA); SIDDIQUI M A) 27 June 1996 whole document ----	1-5
A	KUNITADA S ET AL: "FACTOR XA INHIBITORS" CURRENT PHARMACEUTICAL DESIGN, vol. 2, no. 5, October 1996, pages 531-542, XP002057653 whole content, esp. tables 8 to 10 ----	1-5
A	STILZ H U ET AL: "DISCOVERY OF AN ORALLY ACTIVE NON-PEPTIDE FIBRINOGEN RECEPTOR ANTAGONIST" JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 11, 24 May 1996, pages 2118-2122, XP000578006 whole document, Tables ----	1-5
P,X	WO 98 09987 A (SIDDIQUI M ARSHAD ;ST DENIS YVES (CA); IAF BIOCHEM INT (CA); CODY) 12 March 1998 examples ----	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. Appl. No.

PCT/US 98/07159

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9309133	A	13-05-1993		EP 0610432 A JP 7501057 T US 5539104 A		17-08-1994 02-02-1995 23-07-1996
WO 9640744	A	19-12-1996		AU 6476196 A EP 0832102 A		30-12-1996 01-04-1998
WO 9535313	A	28-12-1995		US 5714499 A AU 2905495 A CA 2192211 A EP 0765339 A JP 10503177 T AU 2863095 A CA 2192210 A EP 0802923 A JP 10503176 T NO 965353 A WO 9535311 A US 5703208 A		03-02-1998 15-01-1996 28-12-1995 02-04-1997 24-03-1998 15-01-1996 28-12-1995 29-10-1997 24-03-1998 17-02-1997 28-12-1995 30-12-1997
WO 9619491	A	27-06-1996		AU 4062795 A AU 4062895 A AU 4250596 A AU 4250896 A CA 2208772 A CA 2208773 A WO 9619483 A EP 0802916 A EP 0799240 A FI 972466 A LT 97132 A NO 972892 A PL 320965 A ZA 9510960 A ZA 9510961 A		27-06-1996 04-07-1996 10-07-1996 10-07-1996 27-06-1996 27-06-1996 27-06-1996 29-10-1997 08-10-1997 19-08-1997 25-03-1998 20-08-1997 24-11-1997 09-07-1996 09-07-1996
WO 9809987	A	12-03-1998		AU 4172397 A		26-03-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.